Our results add to an increasing body of evidence linking CAV1 and CAV2 genes to ALS, help to elucidate the role of their enhancer mutations and gene expression in ALS, and support the positioning of CAV1/2 genes as potential targets for the development of treatment. The gene discussed is CAV1; the disease is amyotrophic lateral sclerosis.